About Us

Instem is a leading provider of IT solutions to the global life sciences  market which help clients collect, analyze, report and submit data to regulatory agencies with confidence while helping them reveal new insights from public and proprietary data. The Group is focussed on the early development stages, from late discovery and lead optimisation through to Phase III clinical evaluation and regulatory submission management. Instem products and services increase client productivity and power the processes that lead to safer and more effective drug and chemical products. As the number one global provider, management estimates that approximately half of the world’s preclinical drug safety data has been collected over the last 20 years using Instem software.

Instem has over 600 customers with its blue chip customer base consisting of the leading pharmaceutical, medical device, chemical and contract research organisations as well as academic, government and privately funded research institutions across many sites worldwide. These include all of the top 25 pharmaceutical and biotech companies such as GlaxoSmithKline and AstraZeneca.

The business has been accelerating its growth trajectory, both organically and acquisitively, by introducing new software solutions for the Early Development market, providing technology-enabled outsourced services and extending its presence in the Asia-Pacific, a region where the market has been growing strongly and Instem’s penetration had been modest.

Instem clients are reducing their research and development timelines generating significant patent-protected revenue

Corporate Timeline

2021 Acquisition of The Edge Software Consultancy Ltd. and d-wise, Inc. in March
Acquisition of PDS Pathology Data Systems Ltd. in September
2020 Placing of 3,620,690 New Ordinary Shares to raise £15.0 million
2019 Acquisition of Leadscope, Inc. in November
2016 Acquisition of NOTOCORD® in September
2016 Acquisition of Samarind Limited in May
2016 Placing of 2,500,000 New Ordinary Shares to raise £5.0 million
2013 Acquisition of Perceptive Instruments in November
2013 Acquisition of Logos Technologies in May
2011 Acquisition of BioWisdom Ltd in March
2010 Placing raising £9.15 million and Admission to the AIM market of the London Stock Exchange
2010 Repayment of outstanding Alchemy debt
Chinese subsidiary established in Shanghai
2002 Secondary MBO for an EV of £11.8m
Focus on dominating niche in Early Development Safety Assessment & repaying debt
2001 Provantis software suite launched
1999 Instem Life Science Systems acquired Fraser-Williams Data Systems
1998 Instem Life Science Systems demerged from Instem plc
1997 Instem plc taken private by management backed by Alchemy Partners
1996 Acquired Apoloco - a pharma software business
1994 Phil Reason appointed to run Instem Life Science Systems
1992 Instem Life Science Systems division formally established as part of Instem plc